They were randomly divided into 6 groups. Treatment groups received treatment of BAL+ MARS, BAL+ SPE+ CHDF or BAL+ SPE+HP respectively. Control groups received treatment of MARS, SPE+ CHDF or SPE+HP respectively.
英
美
- 選取120例晚期慢性重型肝炎患者,隨機均分為6組,治療組分別接受BAL+MARS、BAL+SPE+CHDF和BAL+SPE+HP治療,對照組分別接受MARS、SPE+CHDF和SPE+HP治療。
